CY1120087T1 - Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τους - Google Patents
Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τουςInfo
- Publication number
- CY1120087T1 CY1120087T1 CY20181100194T CY181100194T CY1120087T1 CY 1120087 T1 CY1120087 T1 CY 1120087T1 CY 20181100194 T CY20181100194 T CY 20181100194T CY 181100194 T CY181100194 T CY 181100194T CY 1120087 T1 CY1120087 T1 CY 1120087T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tumor
- ecm
- addition
- disclosure relates
- composition
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3310CH2011 | 2011-10-04 | ||
| PCT/IB2012/055334 WO2013050962A1 (en) | 2011-10-04 | 2012-10-04 | Ecm composition, tumor microenvironment platform and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120087T1 true CY1120087T1 (el) | 2018-12-12 |
Family
ID=54261176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100194T CY1120087T1 (el) | 2011-10-04 | 2018-02-21 | Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τους |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US20140228246A1 (enExample) |
| EP (1) | EP2764099B1 (enExample) |
| JP (2) | JP6147259B2 (enExample) |
| AU (1) | AU2012320088C1 (enExample) |
| CA (1) | CA2850274A1 (enExample) |
| CY (1) | CY1120087T1 (enExample) |
| DK (1) | DK2764099T3 (enExample) |
| ES (1) | ES2660975T3 (enExample) |
| HU (1) | HUE036537T2 (enExample) |
| NO (1) | NO2764099T3 (enExample) |
| PT (1) | PT2764099T (enExample) |
| SG (1) | SG11201401183UA (enExample) |
| TR (1) | TR201802420T4 (enExample) |
| WO (1) | WO2013050962A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9810242B2 (en) | 2013-05-31 | 2017-11-07 | Eaton Corporation | Hydraulic system and method for reducing boom bounce with counter-balance protection |
| US20160287533A1 (en) * | 2013-11-27 | 2016-10-06 | Research Foundation Of The City University Of New York | Activity Enhancing Curcumin Compositions and Methods of Use |
| CN103966168B (zh) * | 2014-05-19 | 2017-05-03 | 广州恒迪生物科技有限公司 | 肿瘤活组织体外培养系统及培养方法 |
| WO2016154082A2 (en) * | 2015-03-23 | 2016-09-29 | Tang Yao | Methods of primary tissue culture and drug screening using autologous serum and fluids |
| US20180089363A1 (en) * | 2015-04-22 | 2018-03-29 | Ono Pharmaceutical Co., Ltd. | Method for extracting lead compound, method for selecting drug discovery target, device for creating scatter diagram, and data visualization method and visualization device |
| GB201507894D0 (en) * | 2015-05-08 | 2015-06-24 | Imagen Biotech Ltd | Personalised media |
| WO2017070353A1 (en) * | 2015-10-20 | 2017-04-27 | Celcuity Llc | Methods of preparing a primary cell sample |
| CN106047788A (zh) * | 2016-08-22 | 2016-10-26 | 上海逍鹏生物科技有限公司 | 一种适用于高密度细胞培养体系的培养基 |
| GB2555787A (en) * | 2016-11-07 | 2018-05-16 | Landberg Goran | Diagnostic methods |
| WO2018148336A1 (en) * | 2017-02-08 | 2018-08-16 | Mitra Rxdx, Inc. | Method of predicting clinical outcome of anticancer agents |
| WO2018185760A1 (en) | 2017-04-05 | 2018-10-11 | Yeda Research And Development Co. Ltd. | Ex-vivo culture system and methods of using same |
| IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| WO2019164951A1 (en) * | 2018-02-22 | 2019-08-29 | Mitra Rxdx, Inc. | Methods of predicting response to temporally sequenced combination therapy |
| GB201818885D0 (en) * | 2018-11-20 | 2019-01-02 | Precomb Therapeutics Ag | 3d human cancer model-based combinatiorial drug development method |
| WO2020172591A1 (en) * | 2019-02-22 | 2020-08-27 | Mitra Rxdx, Inc. | A method to predict a patient's response to an anti-cancer drug from an expression level of a set of genes |
| CA3130930A1 (en) * | 2019-03-19 | 2020-09-24 | Kyuson Yun | Methods and systems for evaluation of cell samples |
| CN112961830A (zh) * | 2021-02-25 | 2021-06-15 | 重庆医科大学附属口腔医院 | 口腔鳞癌组织脱细胞基质及其制备方法和应用 |
| CA3219233A1 (en) | 2021-06-06 | 2022-12-15 | Ravid STRAUSSMAN | Combined treatment for cancer |
| CN113774025B (zh) * | 2021-08-26 | 2023-07-14 | 湖南丰晖生物科技有限公司 | 一种结直肠癌顺铂耐药株的构建方法 |
| WO2023067582A1 (en) * | 2021-10-23 | 2023-04-27 | Mazumdar Shaw Medical Foundation | Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression |
| US12312631B1 (en) | 2022-06-15 | 2025-05-27 | SageMedic Corporation | High-throughput multiplexed sensitivity and resistance assay |
| PL444462A1 (pl) * | 2023-04-18 | 2024-10-21 | Uniwersytet Medyczny W Białymstoku | Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi |
| CN121320340A (zh) * | 2025-07-23 | 2026-01-13 | 广西医科大学第二附属医院(广西医科大学第二临床医学院) | 可抑制肿瘤生长的siRNA及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508188A (en) * | 1994-01-21 | 1996-04-16 | The Regents Of The University Of California | Method of growing cells in a mammal |
| FR2842822B1 (fr) * | 2002-07-26 | 2004-10-01 | Roussy Inst Gustave | Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales |
| US8071135B2 (en) * | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
| US20120213706A1 (en) * | 2009-04-15 | 2012-08-23 | University Of Medicine And Dentistry Of New Jersey | Reconstituted tumor microenvironment for anticancer drug development |
| US20130071864A1 (en) * | 2010-05-25 | 2013-03-21 | Makoto Watanabe | Colorectal cancer marker vitronectin and method for analyzing vitronectin concentration in blood sample |
-
2012
- 2012-10-04 NO NO12838648A patent/NO2764099T3/no unknown
- 2012-10-04 JP JP2014534027A patent/JP6147259B2/ja not_active Expired - Fee Related
- 2012-10-04 TR TR2018/02420T patent/TR201802420T4/tr unknown
- 2012-10-04 US US14/347,616 patent/US20140228246A1/en not_active Abandoned
- 2012-10-04 DK DK12838648.9T patent/DK2764099T3/en active
- 2012-10-04 SG SG11201401183UA patent/SG11201401183UA/en unknown
- 2012-10-04 EP EP12838648.9A patent/EP2764099B1/en not_active Not-in-force
- 2012-10-04 CA CA2850274A patent/CA2850274A1/en not_active Abandoned
- 2012-10-04 ES ES12838648.9T patent/ES2660975T3/es active Active
- 2012-10-04 PT PT128386489T patent/PT2764099T/pt unknown
- 2012-10-04 HU HUE12838648A patent/HUE036537T2/hu unknown
- 2012-10-04 AU AU2012320088A patent/AU2012320088C1/en not_active Ceased
- 2012-10-04 WO PCT/IB2012/055334 patent/WO2013050962A1/en not_active Ceased
-
2016
- 2016-09-12 JP JP2016177434A patent/JP6378273B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-21 CY CY20181100194T patent/CY1120087T1/el unknown
- 2018-10-26 US US16/172,606 patent/US20190170730A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/422,031 patent/US20190353640A1/en not_active Abandoned
- 2019-05-24 US US16/422,059 patent/US20190346428A1/en not_active Abandoned
- 2019-05-24 US US16/422,052 patent/US20190383796A1/en not_active Abandoned
- 2019-05-24 US US16/422,023 patent/US20190383795A1/en not_active Abandoned
- 2019-05-24 US US16/422,045 patent/US20200064333A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012320088A1 (en) | 2014-05-01 |
| US20190353640A1 (en) | 2019-11-21 |
| EP2764099B1 (en) | 2017-11-22 |
| US20190170730A1 (en) | 2019-06-06 |
| JP6147259B2 (ja) | 2017-06-14 |
| PT2764099T (pt) | 2018-02-28 |
| CA2850274A1 (en) | 2013-04-11 |
| EP2764099A1 (en) | 2014-08-13 |
| NO2764099T3 (enExample) | 2018-04-21 |
| JP2014534809A (ja) | 2014-12-25 |
| DK2764099T3 (en) | 2018-02-26 |
| US20190383795A1 (en) | 2019-12-19 |
| TR201802420T4 (tr) | 2018-03-21 |
| US20190383796A1 (en) | 2019-12-19 |
| JP2017061448A (ja) | 2017-03-30 |
| SG11201401183UA (en) | 2014-09-26 |
| JP6378273B2 (ja) | 2018-08-22 |
| ES2660975T3 (es) | 2018-03-26 |
| WO2013050962A1 (en) | 2013-04-11 |
| US20190346428A1 (en) | 2019-11-14 |
| US20200064333A1 (en) | 2020-02-27 |
| AU2012320088B2 (en) | 2015-07-02 |
| HUE036537T2 (hu) | 2018-07-30 |
| US20140228246A1 (en) | 2014-08-14 |
| EP2764099A4 (en) | 2015-05-06 |
| AU2012320088B9 (en) | 2015-07-16 |
| AU2012320088C1 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tang et al. | Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response | |
| Wu et al. | Role of cancer stem cells in cholangiocarcinoma and therapeutic implications | |
| Xie et al. | Single‐cell RNA sequencing elucidated the landscape of breast cancer brain metastases and identified ILF2 as a potential therapeutic target | |
| Xu et al. | Three-dimensional in vitro tumor models for cancer research and drug evaluation | |
| CN105143883B (zh) | 基于细胞的药物筛选分析方法和其用途 | |
| BR112014028881A2 (pt) | populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células | |
| MX380588B (es) | Ratones de m-csf humanizada. | |
| EP4083233A3 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| Dominijanni et al. | Manipulating the tumor microenvironment in tumor organoids induces phenotypic changes and chemoresistance | |
| Rios et al. | The complexities and caveats of lineage tracing in the mammary gland | |
| BR112013024760A2 (pt) | monitoramento de concentrações de eletrólito em sistemas de bateria de fluxo redox | |
| WO2014071279A3 (en) | Gene fusions and alternatively spliced junctions associated with breast cancer | |
| Spagnol et al. | Patient derived organoids (PDOs), extracellular matrix (ECM), tumor microenvironment (TME) and drug screening: state of the art and clinical implications of ovarian cancer organoids in the era of precision medicine | |
| Vella et al. | 3D cell culture models in research: applications to lung cancer pharmacology | |
| AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
| BRPI0908747A2 (pt) | Ligantes esteróides e seu uso em modulação de comutador genético | |
| Xu et al. | Recent advances in microfluidic models for cancer metastasis research | |
| EP2619587A4 (en) | BIOMARKER FOR PREDICTING THE REPRODUCTION OF A COLORECTAL CARCINOMA | |
| WO2009055823A3 (en) | Method to predict responsiveness of breast cancer to polyaminetype chemotherapy | |
| Singh et al. | Controlled three-dimensional tumor microenvironments recapitulate phenotypic features and differential drug response in early vs advanced stage breast cancer | |
| Krysko et al. | In vitro veritas: from 2D cultures to organ-on-a-chip models to study immunogenic cell death in the tumor microenvironment | |
| Kokkinos et al. | Does the microenvironment hold the hidden key for functional precision medicine in pancreatic cancer? | |
| Kyo et al. | Clinical landscape of PARP inhibitors in ovarian cancer: molecular mechanisms and clues to overcome resistance | |
| HK1215875A1 (zh) | 用於监视放射治疗癌症反应的方法和试剂盒 | |
| EP2670867A2 (en) | A method for detecting chromosome structure and gene expression simultaneously in single cells |